Dose escalation schedule (revision 29)
Old revision·11:48, 31 Mar 2026·HOMA_Hettie
| Dose escalation scheduleDosing practice | |
|---|---|
Stepwise increases held long enough for tolerance to develop at each level. | |
| Purpose | Tolerability, not efficacy |
| Typical step interval | 4 weeks for weekly agents |
| Limiting effect | Gastrointestinal adverse events |
| Topic infobox · conventions | |
A dose escalation schedule is a planned stepwise increase from a starting dose to a maintenance dose. For incretin agonists it exists to manage tolerability: the starting dose is generally below the effective range, and its purpose is to allow gastrointestinal adaptation before an effective dose is reached.[1]
Step intervals for weekly agents are conventionally four weeks, which is approximately the time to steady state for a peptide with a half-life of several days. Escalating faster raises the dose before the previous step is fully expressed, so both exposure and adverse effects accumulate.[2]
Compressing an escalation predictably increases gastrointestinal adverse events and discontinuation. This is one of the better-characterised relationships in the field, since the escalation schedules used in trials were themselves selected on tolerability grounds.[3]
Why escalation works
[edit]Nausea and vomiting from incretin agonism attenuate with continued exposure at a constant dose, an adaptation associated with the attenuation of the delay in gastric emptying over the same period. Escalation exploits that adaptation by holding each dose long enough for it to occur before increasing.[1]
The insulinotropic and appetite effects do not attenuate in the same way, so the adaptation is selective: tolerability improves while efficacy is retained. This asymmetry is what makes the strategy work at all.
The four-week step interval matches the pharmacokinetics. With a half-life of about seven days, steady state is reached in four to five weeks, so a step held for four weeks is assessed at close to its full expression. A shorter step assesses a dose whose effect is still increasing.[2]
Representative schedules
[edit]| Product class | Starting dose | Steps | Interval |
|---|---|---|---|
| Weekly Semaglutide, obesity | 0.25 mg | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg | 4 weeks |
| Weekly Tirzepatide | 2.5 mg | 2.5 → 5 → 10 → 15 mg | 4 weeks |
| Daily Liraglutide, obesity | 0.6 mg | 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg | 1 week |
Daily agents escalate weekly rather than monthly, for the same pharmacokinetic reason in reverse: steady state is reached in days, so a week is ample. The number of steps is similar; the calendar time is very different.[3]
These are the schedules used in the pivotal trials and reflected in product labelling.[4] The table is descriptive of published schedules; it is not guidance, and this wiki gives no dosing advice.
Deviations and their consequences
[edit]Two deviations are commonly discussed. Escalating faster than the schedule increases gastrointestinal events; the trials that established these schedules did so by finding the pace at which discontinuation was acceptable.[3]
Escalating more slowly, or holding at an intermediate dose, is a recognised approach where tolerability is limiting, and product labelling for several agents permits it explicitly. The cost is that the maintenance dose — and therefore the effect size observed in trials at that dose — is not reached.
Restarting after an interruption raises the question of whether adaptation has been lost. Labelling for several products addresses re-escalation after a defined gap, and the gaps specified differ by product. See Missed dose and Prescribing information. Nothing here is medical advice.[1]
See also
- Dose titration
- Missed dose
- Adverse effects of GLP-1 receptor agonists
- Semaglutide
- Tirzepatide
- Gastric emptying
References
- ^ a b c Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
- ^ a b Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." Frontiers in Endocrinology 10:155 (2019). PMID 31031702.
- ^ a b c Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine 384(11):989–1002 (2021). PMID 33567185.
- ^ Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387(3):205–216 (2022). PMID 35658024.